Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.53 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | P4HB | P07237 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13860061 | 0.88 | LPL (0.50) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL4380517 | 0.85 | LPL (0.54) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL13857889 | 0.85 | LPL (0.54) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL25981444 | 0.85 | LPL (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL1129123 | 0.83 | LIPG (0.50) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL25981484 | 0.83 | HTT (0.59) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL4366318 | 0.82 | LPL (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL20818035 | 0.82 | LPL (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL368960 | 0.82 | LPL (0.71) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL1129099 | 0.82 | LPL (0.47) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059176-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2025-02-20 | — | — | US | disclosed |
| US-12162873-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2024-12-10 | — | — | US | disclosed |
| US-20240101545-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | Guangzhou Innocare Pharma Tech Co., Ltd (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | Guangzhou Innocare Pharma Tech Co., Ltd (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | Guangzhou Innocare Pharma Tech Co., Ltd (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20220298153-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2022-09-22 | — | — | US | disclosed |
| US-20220298153-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2022-09-22 | — | — | US | disclosed |
| US-11345695-B2 | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
| US-11345695-B2 | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1670757-B1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-1670757-B1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| EP-1670757-A1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005040110-A1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005040110-A1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345695-B2 | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | BTK, SYK, LYN | LPL 3844/4885LIPG 3749/4885CA1 4009/4885 |
| US-20220298153-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | BTK, SYK, LYN | LPL 3698/4885LIPG 3306/4885CA1 4413/4885 |
| US-20250059176-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | BTK, SYK, LYN | LPL 3698/4885LIPG 3306/4885CA1 4413/4885 |
| US-20240101545-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | BTK, SYK, LYN | LPL 3698/4885LIPG 3306/4885CA1 4413/4885 |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | GRIN1, GRIN3A, GRIK5 | LPL 4234/4885LIPG 4208/4885CA1 1383/4885 |
| US-12162873-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | BTK, SYK, LYN | LPL 3698/4885LIPG 3306/4885CA1 4413/4885 |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | BTK, SYK, LYN | LPL 3698/4885LIPG 3306/4885CA1 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.